Berberine, an isoquinoline alkaloid extracted from coptis, exerts anti-proliferation and anticancer properties. Pyruvate kinase M2 (PKM2) is a key enzyme of aerobic glycolysis and considered as the potential anticancer target. However, the inhibition effects and interaction action between Berberine and PKM2 is not well known. In this study, berberine showed antitumor activity of HCT-116 and HeLa cells with the suppression of cell proliferation. Moreover, berberine inhibited the enzyme activity of PKM2 in cancer cells, but had no impact on PKM2 expression. Further research showed that the interaction between berberine and PKM2 was dynamic fluorescence quenching and the main intermolecular force was hydrogen bonding. These findings revealed that berberine may serve as a therapeutic drug for cancer chemotherapy.
One important feature of metabolism reprogramming in cancer cells is that they undergo glycolysis even in the presence of oxygen, which is defined as aerobic glycolysis, also known as the Warburg effect [1, 2] . Pyruvate kinase M2 (PKM2) is an important ratelimiting enzyme in the glycolytic process, converting phosphoenolpyruvic acid (PEP) and ADP to pyruvate and ATP [2, 3] . PKM2 is not only a prominent enzyme in the glycolytic process, but also an important factor in tumor initiation, angiogenesis and migration. PKM2 can accelerate cell proliferation and tumorigenesis by activating the MEK5 transcription [4] . PKM2 can accelerate tumor angiogenesis by regulating HIF-1α expression [5] . Furthermore, PKM2 can promote colon cancer cell adhesion and migration by activating STAT3 transcription [6] . Studies also reveal that PKM2 is elevated in colorectal cancer patients and is a sensitive and relatively specific marker for gastrointestinal pathology [7, 8] . These findings indicate that PKM2 may display a potential molecular target in cancer therapy. Thus, the discovery of new inhibitors for PKM2 is very significant and urgent.
Traditional Chinese medicine is a treasure trove of many potential small bioactive molecules, having anticancer properties [9] . Berberine is an isoquinoline alkaloid extracted from several herbs, such as Coptis and Hydrastis canadensis (goldenseal) [10, 11] . Berberine is known as its significant antimicrobial activities, which has been used to treat bacteria-associated diarrhea, intestinal parasitic infections, and ocular trachoma infections for several decades [12, 13] . Recently, increasing evidences support that berberine has a significant anticancer property on several tumor cell types [14] [15] [16] [17] [18] . Some studies demonstrate that berberine induces cell cycle arrest and stimulate cancer cell caspase-dependent apoptosis by interacting directly with telomerase, p53, NF-kB and Bax [15, 19, 20] . Some studies also reveal that berberine inhibits metastasis by targeting Rho kinase-mediated ezrin phosphorylation, or by enhancing nucleoside diphosphate kinases NM23-H1 expression in NPC 5-8 F cell line [21, 22] . However, the mechanism of reaction between PKM2 and berberine is unclear. Here, we detected the impact of berberine on PKM2 expression and its activity. We further examined the intermolecular forces between berberine and PKM2 by fluorescence spectroscopy. These findings provides the theoretical basis for exploiting berberine as a target drug for PKM2.
To investigate the targeted anticancer activity of berberine, an MTT assay was used to determine the inhibition of cell proliferation. The result showed that berberine significantly suppressed HCT-116 and HeLa cell growth in a dose-dependent manner. After treatment with different doses of berberine for 24h, the IC50 value of berberine on HCT-116 cell line was 63.6 ± 3.0μM ( Figure 1A ) and HeLa cell line was 157.4 ± 3.8μM ( Figure 1B ).
As an important factor in tumor initiation, angiogenesis and migration, PKM2 is highly expressed in all proliferating cells, such as tumor cells [23] . To identify the result whether berberine affect the expression of PKM2, we subsequently evaluated the changes in the expression level of PKM2 in HCT-116 and HeLa cells treated with berberine. The immunoblot analysis revealed that berberine had no effect on the expression profile of PKM2 in HCT-116 cells and HeLa cells ( Figure 2 ). PKM2 can accumulate glycolytic intermediates and channel them into the biosynthesis of nucleotide and amino acids, thereby contributing to tumor cell growth [24] . In order to clarify the effects of berberine on PKM2 activity, pyruvate kinase assay kit was used to evaluate the changes of PKM2 activity. The results showed that berberine significantly inhibited the PKM2 activity of HCT-116 cells and HeLa cells in a dose-dependent manner ( Figure 3 ). The IC50 values of berberine on HCT-116 cell line was 290.8 ± 9.4μM ( Figure 3A ) and HeLa cell line was 162.3 ± 3.6μM, respectively ( Figure 3B ). The interaction between fluorescent molecules and other molecules adapts the fluorescence intensity weakening or disappearance known as fluorescence quenching. In protein molecules, the fluorescent is caused by 3 amino acid residues, including tryptophan (Trp), tyrosine (Tyr), and phenylalanine (Phe). However, tryptophan (Trp) is responsible for the most powerful activity to emit fluorescence. Therefore, we can take the change of fluorescence intensity of Trp as a probe to follow the protein's conformation variation [25, 26] . Under our experimental condition, the fluorescence intensity of berberine and other reagents are so weak that their impacts can be ignored safely. The effect of berberine on PKM2 fluorescence intensity is shown in Figure 4 . It's obvious that the fluorescence intensity of PKM2 quenched gradually with the addition of berberine into the cuvette.
Fluorescence quenching can be divided into two types, namely, dynamic quenching and static quenching. They can be distinguished with the following method: at a certain range of temperature, the quenching constant (K sv ) of dynamic quenching will rise with the increase in temperature, while the case of static quenching is the opposite. In order to confirm the quenching mechanism, the value of K sv can be calculated from the Stern-Volmer equation [27] :
Here, F 0 and F are fluorescence intensities of PKM2 before and after the reaction with berberine. K sv is the dynamic quenching constant.
[Q] is the concentration of berberine, and τ 0 represents the average life of biomolecule without quencher, and its value is about 10 -8 s. K q is the rate constant in the process of double molecule quenching.
According plots of linear equations with the Stern-Volmer equation, the values of K sv , K q were obtained by F 0 /F vs [Q] at different temperature, and shown in Table 1 . From Table 1 , we can see that the value of K sv is increased with the increase the temperature. This result suggests that the process of fluorescence quenching is a dynamic quenching. According to the following thermodynamic equations [28] , thermodynamic parameters were calculated and listed in Table 2 .
Ln(k 2 /k 1 ) = (1/T 1 -1/T 2 ) ΔH/R (4). As seen from the Table 2 , the values of ΔS, ΔH, and ΔG are all negative, which reveals that the binding of berberine with PKM2 is a spontaneous process with releasing energy and driven mainly by enthalpy than entropy. Therefore, it can be concluded that hydrogen bonding could play a dominant role in the reaction between berberine and PKM2.
Recent studies reveal that PKM2 is an important factor in carcinogenesis and tumor progression. PKM2 has an critical role in glycolytic intermediates, inflammatory cytokine production and cancer progression [29] . Thus, it is an important and urgent subject to find a drug which has a significant inhibition effect on PKM2 protein expression or its enzyme activity in pharmacological researches [24] .
Berberine, a bioactivity agent widely distributed in herbs, has been indicated to possess a significant anticancer property. Recently, some mechanisms have been documented for berberine's antitumor activity, which mainly involved in cell cycle arrest, metastasis Berberine can suppress cellular proliferation in HCT-116 cells and HeLa cells Natural Product Communications Vol. 12 (9) 2017 1417 inhibition and apoptosis induction [18, 20, 21, 30] . However, the effect of berberine on PKM2 is still unclear. In this study, we find that berberine is a novel inhibitor of PKM2 enzyme activity.
Berberine has a significant antitumor activity of HCT-116 and HeLa cells by suppression of tumor cell proliferation in a dosedependent manner (Figure 1 ). This result demonstrates that berberine has a significant anticancer property on several kinds of tumor cells [14] [15] [16] [17] [18] . As PKM2 is highly expressed in tumor cells and the change of its expression or metabolic activity will affect tumor progression [23] . We subsequently evaluate the expression level of PKM2 with berberine treatment. However, we find that berberine doesn't change PKM2 expression in HCT-116 cells and HeLa cells (Figure 2 ). This result indicates that the inhibition of berberine on cancer cells doesn't have any relationship with the expression of PKM2 protein. There may exsit some else mechanisms. So we then determine the effects of berberine on PKM2 activity. We find berberine has a strong inhibitory activity against PKM2 enzyme of HCT-116 cells and HeLa cells in a dosedependent manner (Figure 3 ). This result indicates that one reason for the anticancer activity of berberine may be due to inhibition of PKM2 enzyme activity. Further, we find that there exerts an interaction between berberine and PKM2, and the main intermolecular force was hydrogen bonding ( Table 1 and 2).
A main problem in cancer treatment is resistance in chemotherapeutic treatment, which is formed by lactate and pyruvate [30] . Berberine showed inhibitory effect of PKM2, which contributed to a decrease in the amount of lactate and pyruvate. Thus, berberine have potential to be used as a combining chemotherapeutic drug for cancer treatment.
Altogether, our results indicate that berberine can suppress cellular proliferation in HCT-116 cells and HeLa cells. It may be related to the inhibition of PKM2 enzyme activity. Furthermore, the result of fluorescence spectroscopy analysis demonstrates that the main intermolecular force between berberine and PKM2 is hydrogen bonding force. These finding may contribute to understanding the role of berberine in cancer treatment and help to the development of berberine and its derivatives with more efficacy for clinical application.
Experimental

Reagents and antibodies:
Berberine was purchased from J&K Scientific (Beijing, China), which was dissolved in DMSO at the concentration of 40mM as stock solution and saved at -80℃. RPMI-1640 medium and DMEM/F-12 (v/v = 1:1) medium were obtained from Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was from Gibco BRL (NY, USA). PKM2 antibody was purchased from Cell Signaling Technology (Beverly, MA). GAPDH antibody was obtained from Abmart (Shanghai, China). His-PKM2 was purchased from Sino Biological Inc (Beijing, China). The pyruvate kinase assay kit was from Nanjing JianCheng Bioengineering Institute (Nanjing, China).
Cell culture: Human colorectal carcinoma HCT-116 cells and human cervical cancer HeLa cells were obtained from American Type Culture Collection (Manassas, VA) and maintained in DMEM/F-12 (v/v = 1:1) medium or RPMI 1640 medium supplemented with 10% FBS and 1% penicillin at 37°C in 5% CO 2 incubator.
MTT assay: Growth inhibitory effects of berberine on HCT-116 and HeLa were determined using a MTT assay. Cells were plated in 96-well plates at 3000 per well and incubated at 37°C in 5% CO 2 incubator. After 24h, these cells were treated with berberine for 24h. Then added 20μL MTT solution per well and incubated for another 4h at 37°C, followed by adding 150μL DMSO. The absorbance was measured at 570nm.
SDS-PAGE and western blot:
To investigate the PKM2 expression changes with berberine treatment, cancer cells were treated with different concentrations of berberine for 24h at 37°C. Then these cells were collected and lysed to extract total proteins. BCA protein assay was used to measure the total protein concentrations. 50mg of cell lysate was added to 10% SDS-PAGE to separate, then transferred to polyvinylidene fluoride (PVDF). After, blocking solution (5% fresh milk in TBS plus Tween-20) was used to block PVDF membranes at room temperature for 1 h. Then, PVDF membranes were incubated with primary antibody by incubation overnight at 4°C and incubated with secondary antibodies for 2h at room temperature. The signals were recorded by using enhanced chemoluminescence.
Pyruvate kinase assay:
The pyruvate kinase assay was performed via a pyruvate kinase assay kit, according to the method reported by the manufacturer's instructions. In the presence of adenosine diphosphate, pyruvate kinase catalytic phosphoenolpyruvate converted to pyruvate. In the case of the presence of NADH, pyruvate is converted to lactate LDH [31] . The 1.155mL mixed solution was added to 20μL of 10ng/μL recombinant human PKM2, and the mixture was preincubated for 10min. The pyruvate kinase activity was measured by a continuous LDH coupled assay and calculated by monitoring the change of absorbance at 340nm resulting from the oxidation of NADH. The reaction catalyzed by LDH is more efficient than the PK reaction, the rate of NADH fluorescence loss corresponds to PK activity One unit of the pyruvate kinase activity here was defined as 1μmol NADH oxidized per minute at 37°C and pH 7.6 [29, 32] .
Fluorescence spectra measurements:
A quantitative analysis of the potential interaction between the PKM2 and berberine was measured by fluorometric titration. The sample of His-PKM2 proteins (1×10 -6 M) was prepared by diluting into phosphate buffer (pH 6.8) and berberine was in double distilled water. The His-PKM2 solution of 3 mL was added to quartz cells at a given temperature and was titrated by successive additions of berberine until arriving a final volume of 100μL. Then the mixture was kept 5min to give them enough reaction time before the measurements. Fluorescence spectra of His-PKM2 and berberine mixture were recorded in the range from 305 to 450nm. Both slits of excitation and emission were 10.5nm with an excitation wavelength at 295nm and an optical path of 10mm.
Statistical analysis:
These results were shown as mean ± standard deviation (SD) from three independent experiments. Differences among two groups were evaluated by Student's t-test. If values of less than 0.05 (p < 0.05), the date were considered significant.
